Расстройства депрессивного спектра в неврологической практике: есть ли место под солнцем, или кто должен лечить пациентов?

Список литературы

1. 1. Klineova S. et al. Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis // Multiple Sclerosis Journal. – 2020. -Vol. 26. – №. 9. -p. 1111–1120
2. 2. Lebrun C. et al. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson's disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines // Journal of clinical psychology. – 2020. -Vol. 76. – №. 3. -p. 356–376
3. 3. Kumral E., Bayam F.E. The Role of Neurologist in the Assessment and Treatment of Depression //Turkish Journal of Neurology/Turk Noroloji Dergisi. – 2020. -Vol. 26. – №. 1
4. 4. Nabulsi L. et al. Frontolimbic, frontoparietal, and default mode involvement in functional dysconnectivity in psychotic bipolar disorder //Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. – 2020. -Vol. №. 2. -p. 140–151
5. 5. Güntürkün O., Ströckens F., Ocklenburg S. Brain lateralization: A comparative perspective //Physiological reviews. – 2020. -Vol. 100. – №. 3. -p. 1019–1063
6. 6. Erlangsen A. et al. Association between neurological disorders and death by suicide in Denmark //Jama. – 2020. -Vol. 323. – №. 5. -p. 444–454
7. 7. Chan Y. L. E. et al. Treatment-Resistant depression enhances risks of dementia and Alzheimer’s disease: A nationwide longitudinal study //Journal of Affective Disorders. – 2020. -Vol. 274. -p. 806–812
8. 8. World Health Organization et al. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. – World Health Organization, 1993. -Vol. 2
9. 9. American Psychiatric Association et al. Diagnostic and statistical manual of mental disorders (DSM-5®). – American Psychiatric Pub, 2013
10. 10. Gaebel W., Zielasek J., Reed G. M. Mental and behavioural disorders in the ICD-11: concepts, methodologies, and current status //Psychiatria polska. – 2017
11. 11. Carrozzino D. et al. The Hamilton Rating Scales for Depression: a critical review of clinimetric properties of different versions //Psychotherapy and psychosomatics. – 2020. -Vol. 89. – №. 3. -p. 133–150
12. 12. Ghaemi S. N. Using Psychiatric Rating Scales in Clinical Trials: A Proposal //Journal of Clinical Psychopharmacology. – 2020. -Vol. 40. – №. 5. -p. 433–435
13. 13. Perna G. et al. Personalized psychiatry and depression: the role of sociodemographic and clinical variables //Psychiatry investigation. – 2020. – Vol. 17. – №. 3. -p. 193
14. 14. Sinanović O. Psychiatric disorders in neurological diseases //Mind and Brain. – Springer, Cham, 2020. -p. 65–79
15. 15. Kenangil G. et al. Alexithymia, depression, and cognition in patients with Parkinson’s disease //Acta Neurologica Belgica. – 2021. -p. 1–7
16. 16. Tran T. et al. What is normal cognition in depression? Prevalence and functional correlates of normative versus idiographic cognitive impairment //Neuropsychology. – 2021. -Vol. 35. – №. 1. -p. 33
17. 17. Altuğ H. et al. Air pollution is associated with depressive symptoms in elderly women with cognitive impairment //Environment international. – 2020. -Vol. 136. -p. 105448
18. 18. Li Y. et al. Brain structural correlates of depressive symptoms in Parkinson's disease patients at different disease stage //Psychiatry Research: Neuroimaging. – 2020. -Vol. 296. -p. 111029
19. 19. Filipska K. et al. Are depression and dementia a common problem for stroke older adults? A review of chosen epidemiological studies //Psychiatric Quarterly. – 2020. -p. 1–11
20. 20. Zeng Y. Y. et al. Comparison of poststroke depression between acute ischemic and hemorrhagic stroke patients //International Journal of Geriatric Psychiatry. – 2020
21. 21. Chaturvedi P. et al. Depression impedes neuroplasticity and quality of life after stroke //Journal of Family Medicine and Primary Care. – 2020. – Vol. 9. – №. 8. -p. 4039
22. 22. Maddula M., Munshi S. K. Readmission to hospital after stroke //Stroke in the Older Person. – 2020. -p. 425
23. 23. Alegiani A. C. et al. Quality of Stroke Patient Information Applied in Randomized Controlled Trials-Literature Review //Frontiers in neurology. – 2020. -Vol. 11. -p. 1603
24. 24. Kowalska K. et al. Early Depression Independently of Other Neuropsychiatric Conditions, Influences Disability and Mortality after Stroke (Research Study-Part of PROPOLIS Study) //Biomedicines. – 2020. -Vol. 8. – №. 11. -p. 509
25. 25. Volz M., Ladwig S., Werheid K. Gender differences in post-stroke depression: A longitudinal analysis of prevalence, persistence and predictive value of known risk factors //Neuropsychological rehabilitation. – 2021. – Vol. 31. – №. 1. -p. 1–17
26. 26. Fournier L. E. et al. Assessment of the progression of poststroke depression in ischemic stroke patients using the patient health questionnaire-9 //Journal of Stroke and Cerebrovascular Diseases. – 2020. -Vol. 29. – №. 4. -p. 104561
27. 27. Li C. et al. Association between obstructive sleep apnea and risk of poststroke depression: A hospital-based study in ischemic stroke patients //Journal of Stroke and Cerebrovascular Diseases. – 2020. -Vol. 29. – №. 8. -p. 104876
28. 28. Khedr E. M. et al. Post-stroke depression: frequency, risk factors, and impact on quality of life among 103 stroke patients-hospital-based study //The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. – 2020. -Vol. 56. – №. 1. -p. 1–8
29. 29. Sam S. P. et al. Post Stroke Depression and Lesion Location: A Hospital based cross sectional study //Kerala Journal of Psychiatry. – 2020
30. 30. Lavados P. M. et al. Incidence, risk factors, prognosis, and health-related quality of life after stroke in a low-resource community in Chile (ÑANDU): a prospective population-based study //The Lancet Global Health. – 2021
31. 31. Medeiros G. C. et al. Post-stroke depression: A 2020 updated review //General Hospital Psychiatry. – 2020
32. 32. Ladwig S., Werheid K. Determinants of Antidepressant Treatment and Outpatient Rehabilitation Within the First Year After Stroke //Journal of Geriatric Psychiatry and Neurology. – 2020.-p. 0891988720973749
33. 33. Haslam B. S. et al. Chronic pain following stroke: Current treatment and perceived effect //Disability and Health Journal. – 2020. -Vol. 14. – №. 1. -p. 100971
34. 34. Li X., Morton S. M. Effects of chronic antidepressant use on neurophysiological responses to tDCS post-stroke //Neuroscience letters. – 2020. -Vol. 717. -p. 134723
35. 35. Li X., Zhang C. Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis//Journal of affective disorders. – 2020. -Vol. 266. -p. 540–548
36. 36. Sivolap Y. P., Damulin I. V. Stroke and Depression //Neuroscience and Behavioral Physiology. – 2020. -Vol. 50. – №. 6. -p. 683–686
37. 37. Bangalore S. et al. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis //Journal of medical economics. – 2020. -Vol. 23. – №. 3. -p. 262–270
38. 38. Castilla-Guerra L. et al. Pharmacological management of post-stroke depression //Expert review of neurotherapeutics. – 2020. -Vol. 20. – №. 2. – p. 157–166
39. 39. Mikami K. et al. Effective tools to predict depression in acute and subacute phase of ischemic stroke //The Journal of Neuropsychiatry and Clinical Neurosciences. – 2020. -p. appi. neuropsych. 20040076
40. 40. Gong L. et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke-A randomized clinical trial //European Journal of Integrative Medicine. – 2020. -Vol. 35. -p. 101102
41. 41. Prost A. et al. Acute and long-term impairments regarding emotional symptoms and quality of life in patients suffering from transient ischemic attack and stroke //Neurological Research. – 2021. -p. 1–11
42. 42. Lin C. et al. Depressive symptoms after stroke are associated with worse recovery //The International Journal of Psychiatry in Medicine. – 2020. – Vol. 55. – №. 4. -p. 227–238
43. 43. Tang W. K. et al. Depression after subarachnoid hemorrhage: a systematic review //Journal of stroke. – 2020. -Vol. 22. – №. 1. -p. 11
44. 44. Teasell R. et al. Canadian stroke best practice recommendations: rehabilitation, recovery, and community participation following stroke. Part one: rehabilitation and recovery following stroke Update 2019 //International Journal of Stroke. – 2020. -Vol. 15. – №. 7. -p. 763–788
45. 45. Lanctôt K. L. et al. Canadian stroke best practice recommendations: mood, cognition and fatigue following stroke, update 2019 //International Journal of Stroke. – 2020. -Vol. 15. – №. 6. -p. 668–688
46. 46. Brzezińska A. et al. Depression in dementia or dementia in depression? Systematic review of studies and hypotheses //Current Alzheimer Research. – 2020. -Vol. 17. – №. 1. -p. 16–28
47. 47. Wu J. J. et al. Late-life depression and the risk of dementia in 14 countries: a 10-year follow-up study from the Survey of Health, Ageing and Retirement in Europe //Journal of affective disorders. – 2020. -Vol. 274. -p. 671677
48. 48. Brown E. E., Rajji T. K., Mulsant B. H. Why Do Some Older Adults Treated with Antidepressants Progress to Dementia? //The Journal of Clinical Psychiatry. – 2020. -Vol. 81. – №. 5. -p. 0–0
49. 49. Santabarbara J., Villagrasa B., Gracia-Garcia P. Does depression increase the risk of dementia? Updated meta-analysis of prospective studies //Actas Esp Psiquiatr. – 2020. -Vol. 48. – №. 4. -p. 169–180
50. 50. Power M. C. et al. Little progress in reducing relative racial disparities in the incidence and prevalence of dementia in the United States, 2000–2016: Epidemiology: Dementia and risk in underrepresented populations //Alzheimer's & Dementia. – 2020. -Vol. 16. -p. e039905
51. 51. Cao Q. et al. The prevalence of dementia: a systematic review and metaanalysis //Journal of Alzheimer's Disease. – 2020. -Vol. 73. – №. 3. -p. 1157–1166
52. 52. Diniz B. S. et al. Mood Disorders and Dementia: Time for Action //The American Journal of Geriatric Psychiatry. – 2020. -Vol. 28. – №. 5. -p. 542–544
53. 53. Dafsari F. S., Jessen F. Depression-an underrecognized target for prevention of dementia in Alzheimer’s disease //Translational Psychiatry. – 2020. -Vol. 10. – №. 1. -p. 1–13
54. 54. Cantón-Habas V. et al. Depression as a Risk Factor for Dementia and Alzheimer’s Disease //Biomedicines. – 2020. -Vol. 8. – №. 11. -p.457
55. 55. Banning L. C P. et al. The association between biomarkers and neuropsychiatric symptoms across the Alzheimer's disease spectrum //The American Journal of Geriatric Psychiatry. – 2020. -Vol. 28. – №. 7. -p. 735–744
56. 56. Ohoreorovwori U. L. et al. Prevalence of and Severity of Depression among Parkinson Disease Patients //Journal of Advances in Medicine and Medical Research. – 2020. -p. 110–118
57. 57. Lee Y. et al. Prevalence and associated factors of depressive disorder in caregivers of individuals with Parkinson disease //Journal of Geriatric Psychiatry and Neurology. – 2020. -p. 0891988720933359
58. 58. Wiels W., Baeken C., Engelborghs S. Depressive symptoms in the elderly-An early symptom of dementia? A systematic review //Frontiers in pharmacology. – 2020. -Vol. 11. – p. 34
59. 59. Jee H. J. et al. Impact of sleep disorder as a risk factor for dementia in men and women //Biomolecules & therapeutics. – 2020. -Vol. 28. – №. 1. -p. 58
60. 60. Mukku S. S. R. et al. Depression and somatic symptoms in dementia: A narrative review //Journal of Geriatric Mental Health. – 2020. – Vol. 7. – №. 1. -p. 11
61. 61. Lee A. T. C. et al. Risk of Incident Dementia varies with Different Onset and Courses of Depression //Journal of Affective Disorders. – 2020
62. 62. Ritchie K. et al. Trauma and depressive symptomatology in middle-aged persons at high risk of dementia: the PREVENT Dementia Study //Journal of Neurology, Neurosurgery & Psychiatry. – 2021. -Vol. 92. – №. 1. -p. 16–21
63. 63. Ritchie K. et al. Trauma and depressive symptomatology in middle-aged persons at high risk of dementia: the PREVENT Dementia Study //Journal of Neurology, Neurosurgery & Psychiatry. – 2021. -Vol. 92. – №. 1. -p. 16–21
64. 64. Brewster K. et al. Age-related hearing loss, late-life depression, and risk for incident dementia in older adults //The American Journal of Geriatric Psychiatry. – 2020. -Vol. 28. – №. 4. -p. S90-S93
65. 65. Holmquist S., Nordström A., Nordström P. The association of depression with subsequent dementia diagnosis: A Swedish nationwide cohort study from 1964 to 2016 //PLoS medicine. – 2020. -Vol. 17. – №. 1. -p. e1003016
66. 66. Barczyk Z. A., Douglas K. M., Porter R. J. Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review //BJPsych Open. – 2020. -Vol. 6. – №. 6
67. 67. Peakman G. et al. Clinical factors associated with progression to dementia in people with late-life depression: A cohort study of patients in secondary care //BMJ open. – 2020. -Vol. 10. – №. 5. -p. e035147
68. 68. Dias N. S. et al. Depressive disorders in the elderly and dementia: An update //Dementia & neuropsychologia. – 2020. -Vol. 14. – №. 1. -p. 1–6
69. 69. Aajami Z. et al. Relationship between depression and cognitive impairment among elderly: A cross-sectional study //Journal of Caring Sciences. – 2020. -Vol. 9. – №. 3. -p. 148
70. 70. Carr A. L. et al. Depression as a risk factor for dementia in older people with type 2 diabetes and the mediating effect of inflammation //Diabetologia. – 2021. -Vol. 64. – №. 2. -p. 448–457
71. 71. Oh D. J. et al. Chronic subsyndromal depression and risk of dementia in older adults //Australian & New Zealand Journal of Psychiatry. – 2020. -p. 0004867420972763
72. 72. Anstey K. J. et al. Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus //Journal of Alzheimer's Disease. – 2020. – №. Preprint. -p. 1–10
73. 73. Marcum Z. A. et al. Engaging Patients to Design the Systematic Multi-Domain Alzheimer’s Risk Reduction Trial (SMARRT) Intervention: Findings from a Web-Based Survey //Journal of Alzheimer's disease reports. – 2020. №. Preprint. -p. 1–6
74. 74. Lin C. E. et al Association between concurrent antidepressant and hypnotic treatment and the risk of dementia: A nationwide cohort study //Journal of Affective Disorders. – 2020. -Vol. 277. -p. 549–558
75. 75. Bartels C. et al. To be continued? long-term treatment effects of antidepressant drug classes and individual antidepressants on the risk of developing dementia: a German case-control study //The Journal of Clinical Psychiatry. – 2020. -Vol. 81. – №. 5. -p. 0–0
76. 76. Alexopoulos G. S. Mechanisms and treatment of late-life depression //Translational psychiatry. – 2019. -Vol. 9. – №. 1. -p. 1–16
77. 77. Borda M. G. et al. Benzodiazepines and antidepressants: effects on cognitive and functional decline in Alzheimer’s disease and Lewy body dementia //International Journal of Geriatric Psychiatry. – 2020
78. 78. Abdeljalil A. B. et al. Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort //Journal of the American Medical Directors Association. – 2020
79. 79. Keir L. H. M., Breen D. P. New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson’s disease //Journal of neurology. – 2020. -Vol. 267. – №. 1. -p. 288–294
80. 80. Armstrong M. J., Okun M. S. Diagnosis and treatment of Parkinson disease: a review //Jama. – 2020. -Vol. 323. – №. 6. -p. 548–560
81. 81. Jones S. et al. Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment //BJPsych Advances. – 2020. -Vol. 26. – №. 6. -p. 333–342
82. 82. Jin X. et al. The impact of mind-body exercises on motor function, depressive symptoms, and quality of life in Parkinson’s disease: a systematic review and meta-analysis //International journal of environmental research and public health. – 2020. -Vol. 17. – №. 1. -p. 31
83. 83. Zhao N. et al. Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies //CNS Neuroscience & Therapeutics. – 2020
84. 84. Chuquilín-Arista F., Álvarez-Avellón T., Menéndez-González M. Prevalence of depression and anxiety in Parkinson disease and impact on quality of life: a community-based study in Spain //Journal of geriatric psychiatry and neurology. – 2020. -Vol. 33. – №. 4. -p. 207–213
85. 85. Mufti S., LaFaver K. Mood Disorders in Parkinson's Disease //Psychiatric Annals. – 2020. -Vol. 50. – №. 3. -p. 95–99
86. 86. Park J. H. et al. Depressive symptoms are associated with worse cognitive prognosis in patients with newly diagnosed idiopathic Parkinson disease //Psychogeriatrics. – 2020. -Vol. 20. – №. 6. -p. 880–890
87. 87. Kobylecki C. Update on the diagnosis and management of Parkinson's disease //Clinical Medicine. – 2020. -Vol. 20. – №. 4. -p. 393
88. 88. Contarino M. F. et al. Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review //Parkinsonism & Related Disorders. – 2020
89. 89. Ziesen N. K., Kilian H. M., Schlaepfer T. E. Beyond antidepressant effects of deep brain stimulation-A systematic qualitative approach //Personalized Medicine in Psychiatry. – 2020. -Vol. 23. -p. 100063
90. 90. Vissani M., Isaias I. U., Mazzoni A. Deep brain stimulation: a review of the open neural engineering challenges //Journal of Neural Engineering. – 2020. -Vol. 17. – №. 5. -p. 051002
91. 91. Chang Y. P. et al. Risk factors for depression in patients with Parkinson’s disease: A nationwide nested case-control study //PloS one. – 2020. -Vol. 15. – №. 7. -p. e0236443
92. 92. Gu S. C. et al. Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort study //Journal of affective disorders. – 2020. -Vol. 268. -p. 118–126
93. 93. Scherbaum R et al. Parkinson’s Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life //Journal of neurology. – 2020. -Vol. 267. – №. 4. -p. 954–965
94. 94. Assogna F. et al. Drug Choices and Advancements for Managing Depression in Parkinson's Disease //Current neuropharmacology. – 2020. -Vol. 18. – №. 4. -p. 277–287
95. 95. Fabbri M. et al. Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease //Journal of Parkinson's Disease. – 2020. – №. Preprint. -p. 1–9
96. 96. Stuhec M., Stoppe G. Psychopharmacotherapy in Aged Patients //NeuroPsychopharmacotherapy. – 2020. -p. 1–12
97. 97. Iwaki H. et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease //Journal of the neurological sciences. – 2020. -Vol. 414. -p. 116833
98. 98. Nastitie F., Abdulllah S., Nurrohmah S. Analysis of factors associated with early-stage Parkinson’s disease based on daily activities and sleeping behaviour disorder //Journal of Physics: Conference Series. – IOP Publishing, 2021. -Vol. 1722. – №. 1. -p. 012045
99. 99. Konyushok M. Why Neurologists Should Remember About Antidepressants //bipolar disorder. – 2020. -Vol. 2. – №. 4
100. 100. Karnik V. et al. Current Status of Pain Management in Parkinson’s Disease //Canadian Journal of Neurological Sciences. – 2020. -Vol. 47. – №. 3. -p. 336–343
101. 101. Rodrigues-Amorim D. et al. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine //Frontiers in psychiatry. – 2020. -Vol. 11
102. 102. Buhmann C., Kassubek J., Jost W. H. Management of Pain in Parkinson’s Disease //Journal of Parkinson's Disease. – 2020. – №. Preprint. – p. 1–12
103. 103. Aris A. et al. Clinical Trials on Management of Pain in Parkinson’s Disease //Clinical Trials in Parkinson's Disease. – Humana, New York, NY, 2021. -p. 293–321
104. 104. Tai Y. C., Lin C. H. An overview of pain in Parkinson's disease //Clinical Parkinsonism & Related Disorders. – 2020. -Vol. 2. -p. 1–8
105. 105. Nagamine T. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may be a double-edged sword for patients with advanced Parkinson's disease //Asian journal of psychiatry. – 2020. -Vol. 50. -p. 102031102031
106. 106. Greten S. et al. Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis //Journal of Neural Transmission. – 2020. -p. 1–12
107. 107. Javidnia M. et al. Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson’s Disease Parkinson’s Progression Markers Initiative Participants //Journal of Parkinson's disease. – 2020. – №. Preprint. -p. 1–5
108. 108. Милюхина И.В. Применение Вортиоксетина при депрессии у пациентов с болезнью Паркинсона на ранних и развернутых стадиях заболевания / И.В. Милюхина // Неврология, нейропсихиатрия, психосоматика. – 2020. – Т. 12. – №. 5. – С. 40–45
109. 109. Barbato G. et al. Vortioxetine for the treatment of depressive episodes associated with Parkinson’s disease: a case series of six patients //Cited in: EMBASE-Excerpta Medica Database• Index Copernicus• PsycINFO• SCOPUS• Google Scholar• Emerging Sources Citation Index (ESCI), a new edition of Web of Science. -p. 248
110. 110. Behlke L. M., Lenze E. J., Carney R. M. The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases //CNS drugs. – 2020. -p. 1–15
111. 111. Rutten S. et al. Anxiety, depression and sleep disorders in Parkinson's disease: a complex interaction between body and mind //Tijdschrift voor psychiatrie. – 2020. -Vol. 62. – №. 1. -p. 62–72
112. 112. Benedict R. H. B. Cognition in multiple sclerosis: Charcot was right //The Lancet Neurology. – 2020. -Vol. 19. – №. 10. -p. 810
113. 113. Knapik A. et al. Affective Disorder and Functional Status as well as Selected Sociodemographic Characteristics in Patients with Multiple Sclerosis, Parkinson’s Disease and History of Stroke //Medicina. – 2020. -Vol. 56. – №. 3. -p. 117
114. 114. Błachut M. et al. Prevalence of psychiatric disorders among patients with Multiple Sclerosis: a cross-sectional study. – 2020
115. 115. Knowles L. M. et al. Depressive Symptoms and Suicidal Ideation in Progressive Multiple Sclerosis Compared with Relapsing-Remitting Multiple Sclerosis: Results from a Cross-sectional Survey //Archives of physical medicine and rehabilitation. – 2020
116. 116. Romaniuc A. et al. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients //Behavioural neurology. – 2020. -Vol. 2020
117. 117. Silva-Moraes M. H. et al. Suicidal behavior in individuals with Amyotrophic Lateral Sclerosis: a systematic review //Journal of Affective Disorders. – 2020
118. 118. Hanna M., Strober L. B. Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life //Multiple Sclerosis and Related Disorders. – 2020. -Vol. 44. -p. 102261
119. 119. Kellerman Q. D. et al. Risk factors for suicide in a national sample of veterans with multiple sclerosis //Archives of physical medicine and rehabilitation. – 2020. -Vol. 101. – №. 7. -p. 1138–1143
120. 120. Tauil C. B. et al. Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments //Brazilian Journal of Medical and Biological Research. – 2021. -Vol. 54. – №. 3
121. 121. Podda J. et al. Predictors of clinically significant anxiety in people with multiple sclerosis: A one-year follow-up study //Multiple Sclerosis and Related Disorders. – 2020. -Vol. 45. -p. 102417
122. 122. Magyari M., Sorensen P. S. Comorbidity in multiple sclerosis //Frontiers in Neurology. – 2020. – Vol. 11. -p. 851
123. 123. Masuccio F. G. et al. Imaging and depression in multiple sclerosis: a historical perspective //Neurological Sciences. – 2021. -p. 1–11
124. 124. Kuchling J., Paul F. Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders //Frontiers in Neurology. – 2020. -Vol. 11
125. 125. Hauer L., Perneczky J., Sellner J. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications //Journal of Neurology. – 2020. -p. 1–12
126. 126. Lazzarotto A. et al. Selective cerebellar atrophy associates with depression and fatigue in the early phases of relapse-onset multiple sclerosis //The Cerebellum. – 2020. -Vol. 19. – №. 2. -p. 192–200
127. 127. Chisari C. G. et al. An update on the pharmacological management of pain in patients with multiple sclerosis //Expert opinion on pharmacotherapy. – 2020. -Vol. 21. – №. 18. -p. 2249–2263
128. 128. Patten S. B. Current perspectives on co-morbid depression and multiple sclerosis //Expert Review of Neurotherapeutics. – 2020. -Vol. 20. – №. 8. -p. 867–874
129. 129. Di Stefano G. et al. Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis //CNS drugs. – 2020. -Vol. 34. -p. 749–761
130. 130. Plantone D. et al. A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis //Neurological Sciences. – 2020. -p. 1–7
131. 131. Solaro C. et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study //Clinical neuropharmacology. – 2013. -Vol. 36. – №. 4. -p. 114–116
132. 132. Vollmer T. L. et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Duloxetine for the Treatment of Pain in Patients with Multiple Sclerosis //Pain Practice. – 2014. -Vol. 14. – №. 8. -p. 732–744
133. 133. Oliveira R. A. A. et al. Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology //Arquivos de neuro-psiquiatria. – 2020. -Vol. 78. – №. 11. -p. 741–752
134. 134. Hua L. H. et al. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60 //Multiple sclerosis and related disorders. – 2021. -Vol. 47. -p. 102637
135. 135. Sylla M. et al. Prevalence, severity, and associations of depression in people with epilepsy in Guinea: A single-center study //Epilepsy & Behavior. – 2020. -Vol. 113. -p. 107475
136. 136. Ajinkya S., Fox J., Lekoubou A. Trends in prevalence and treatment of depressive symptoms in adult patients with epilepsy in the United States //Epilepsy & Behavior. – 2020. -Vol. 105. -p. 106973
137. 137. Barco A. M. Z., Martínez M. R., Restrepo D. Depression in people with epilepsy. What is the connection? //Revista Colombiana de Psiquiatría (English ed.). – 2020. -Vol. 49. – №. 1. -p. 53–61
138. 138. Mesraoua B. et al. Dramatic outcomes in epilepsy: depression, suicide, injuries, and mortality //Current medical research and opinion. – 2020. -Vol. 36. – №. 9. -p. 1473–1480
139. 139. Theodore W. H. Epilepsy in the Hippocratic collection: Seizures and syndromes //Epilepsy & Behavior. – 2021. -Vol. 115. -p. 107704
140. 140. Kluger B. M. et al. Would people living with epilepsy benefit from palliative care? //Epilepsy & Behavior. – 2020. -p. 107618
141. 141. Mameniškienė R. et al. A Review of Accelerated Long-Term Forgetting in Epilepsy //Brain Sciences. – 2020. -Vol. 10. – №. 12. -p. 945
142. 142. Eloge J. C., Ross D. A., Cooper J. J. Afflicted by the gods: the shared history and neurobiology of psychosis and epilepsy //Biological Psychiatry. – 2020. -Vol. 87. – №. 12. -p. e35-e36
143. 143. Yeung A., Rapoport M. Paradoxical complete and spontaneous resolution of depression, psychosis, and suicidal ideation following a traumatic brain injury //Brain injury. – 2020. -Vol. 34. – №. 10. -p. 1427–1430
144. 144. Gargiulo Á. J. M. et al. Epilepsy and Psychiatric Comorbidities: New Approaches and Perspectives //Psychiatry and Neuroscience Update. – Springer, Cham, 2021. -p. 537–553
145. 145. Patel S. et al. Psychiatric and psychosocial morbidity 1 year after epilepsy surgery //Irish Journal of Psychological Medicine. – 2020. -p. 1–8
146. 146. Solli E. et al. Deciphering the surgical treatment gap for drug-resistant epilepsy (DRE): A literature review //Epilepsia. – 2020. -Vol. 61. – №. 7. -p. 1352–1364
147. 147. Mula M. et al. Psychiatric comorbidities in people with epilepsy //Neurology: Clinical Practice. – 2020
148. 148. Kanner A. M. Psychiatric Comorbidities in Medication-Resistant Epilepsy //Medication-Resistant Epilepsy: Diagnosis and Treatment. – 2020. -p. 256
149. 149. Małgorzata P. et al. Glutamatergic dysregulation in mood disorders: Opportunities for the discovery of novel drug targets //Expert Opinion on Therapeutic Targets. – 2020. -Vol. 24. – №. 12. -p. 1187–1209
150. 150. Rhie S. J., Jung E. Y., Shim I. The role of neuroinflammation on pathogenesis of affective disorders //Journal of exercise rehabilitation. -2020-Vol. 16. – №. 1. -p. 2
151. 151. Marwein S., Biswal S., Acharya P. C. Hormones and Steroids as Neurotransmitters //Frontiers in Pharmacology of Neurotransmitters. – Springer, Singapore, 2020. -p. 447–501
152. 152. Basu T., Maguire J., Salpekar J. A. Hypothalamic-pituitary-adrenal axis targets for the treatment of epilepsy //Neuroscience Letters. – 2021. – p. 135618
153. 153. Barroca N. C. B. et al. Evaluation of the HPA Axis’ Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression //Eneuro. – 2021. -Vol. 8. – №. 1
154. 154. Tolchin B., Hirsch L. J., LaFrance W. C. Neuropsychiatric aspects of epilepsy //Psychiatric Clinics. – 2020. -Vol. 43. – №. 2. -p. 275–290
155. 155. Scott A. J. et al. Systematic review and meta-analysis of anxiety and depression in youth with epilepsy //Journal of pediatric psychology. – 2020. -Vol. 45. – №. 2. -p. 133–144
156. 156. Ertan D. et al. Anticipatory anxiety of epileptic seizures: An overlooked dimension linked to trauma history //Seizure. – 2021. -Vol. 85. -p. 64–69
157. 157. Galicchio S. et al. Self-limited epilepsy with centro-temporal spikes: A study of 46 patients with unusual clinical manifestations //Epilepsy Research. – 2021. -Vol. 169. -p. 106507
158. 158. Melo H. M. et al. Ictal fear is associated with anxiety symptoms and interictal dysphoric disorder in drug-resistant mesial temporal lobe epilepsy //Epilepsy & Behavior. – 2021. -Vol. 115. -p. 107548
159. 159. Gugała-Iwaniuk M. et al. The prevalence of depressive and anxiety symptoms in Polish epilepsy patients-The context of pharmaco-resistance //Epilepsy & Behavior. – 2020. -p. 107522
160. 160. Yin F. et al. Auras in intractable frontal lobe epilepsy: Clinical characteristics, values, and limitations //Epilepsy & Behavior. – 2021. -Vol. 115. -p. 107724
161. 161. Bargalló N., Blanco E. C. How to interpret images in epileptic seizures: correlation between clinical and functional MRI findings //Radiología (English Edition). – 2020. -Vol. 62. – №. 2. -p. 102–111
162. 162. Andrews J. P., Chang E. F. Temporal Neocortical Epilepsy //Stereotactic and Functional Neurosurgery: Principles and Applications. – 2020. – p. 367
163. 163. Thomas R. H., Osland K. Learnings from deaths-the Epilepsy Deaths Register //Epilepsy & Behavior. – 2020. -Vol. 103. -p. 106454
164. 164. Thomas R. H., Craig D. P., Leach J. P. The view of the clinician and the scientist on the family experience of sudden epilepsy deaths //Epilepsy & Behavior. – 2020. -Vol. 103. -p. 106679
165. 165. Pickrell W. O., Kerr M. P. SUDEP and mortality in epilepsy: The role of routinely collected healthcare data, registries, and health inequalities //Epilepsy & Behavior. – 2020. -Vol. 103. -p. 106453
166. 166. Harcourt S. The neuropsychology of epilepsy and suicide: A review //Aggression and violent behavior. – 2020. -p. 101411
167. 167. Wirrell E. C. et al. Self-injurious and suicidal behavior in young adults, teens, and children with epilepsy: A population-based study //Epilepsia. – 2020. -Vol. 61. – №. 9. -p. 1919–1930
168. 168. Kim S. J. et al. Clinical factors associated with suicide risk independent of depression in persons with epilepsy //Seizure. – 2020. -Vol. 80. -p. 86–91
169. 169. Dagar A. et al. Screening for suicidality and its relation to undiagnosed psychiatric comorbidities in children and youth with epilepsy //Epilepsy & Behavior. – 2020. -Vol. 113. -p. 107443
170. 170. Shaikh M. et al. The gut-brain-axis on the manifestation of depressive symptoms in epilepsy: an evidence-driven hypothesis //Frontiers in pharmacology. – 2020. -Vol. 11. -p. 465
171. 171. Clary H. M. M. et al. Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic //Epilepsy & Behavior. – 2020. -Vol. 104. -p. 106907
172. 172. Stefanidou M., Greenlaw C., Douglass L. Mental health issues in transition-age adolescents and young adults with epilepsy //Seminars in Pediatric Neurology. – WB Saunders, 2020. -p. 100856
173. 173. Narapareddy B. R. et al. Treatment of depression after traumatic brain injury: a systematic review focused on pharmacological and neuromodulatory interventions //Psychosomatics. – 2020
174. 174. Teymoori A. et al. Factorial structure and validity of Depression (PHQ-9) and Anxiety (GAD-7) scales after traumatic brain injury //Journal of clinical medicine. – 2020. -Vol. 9. – №. 3. -p. 873
175. 175. Erler K. S., Kew C. L., Juengst S. B. Participation differences by age and depression 5 years after moderate-to-severe traumatic brain injury //International review of psychiatry. – 2020. -Vol. 32. – №. 1. -p. 12–21
176. 176. Albrecht J. S. et al. Treatment of depression after traumatic brain injury reduces risk of neuropsychiatric outcomes //Journal of neurotrauma. – 2020-Vol. 37. – №. 23. -p. 2542–2548
177. 177. Peppel L. D., Ribbers G. M., Heijenbrok-Kal M. H. Pharmacological and non-pharmacological interventions for depression after moderate-to severe traumatic brain injury: a systematic review and meta-analysis //Journal of neurotrauma. – 2020. -Vol. 37. – №. 14. -p. 1587–1596
178. 178. Elliott J. E. et al. Posttraumatic stress disorder increases the odds of REM sleep behavior disorder and other parasomnias in Veterans with and without comorbid traumatic brain injury //Sleep. – 2020. -Vol. 43. – №. 3. -p. zsz237
179. 179. McIntyre A. et al. Anxiety, depression, and quality of life among subgroups of individuals with acquired brain injury: The role of anxiety sensitivity and experiential avoidance //Neurorehabilitation. – 2020. – №. Preprint. p. 1–9
180. 180. Marinkovic I. et al. Prognosis after mild traumatic brain injury: influence of psychiatric disorders //Brain sciences. – 2020. -Vol. 10. – №. 12. -p. 916
181. 181. Hicks A. J. et al. Efficacy and Harms of Pharmacological Interventions for Anxiety after Traumatic Brain Injury: Systematic Review //Journal of Neurotrauma. – 2020
182. 182. Fakhoury M. et al. Depression following traumatic brain injury: a comprehensive overview //Reviews in the Neurosciences. – 2020. -Vol. 1. – №. ahead-of-print
183. 183. Albayram O., Albayram S., Mannix R. Chronic traumatic encephalopathy-a blueprint for the bridge between neurological and psychiatric disorders //Translational Psychiatry. – 2020. -Vol. 10. – №. 1. -p. 1–8
184. 184. Zhou Y. et al. Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury //Cell Communication and Signaling. – 2020. – Vol. 18. -p. 1–16
185. 185. Mukherjee S. et al. Neuroinflammatory mechanisms of post-traumatic epilepsy //Journal of neuroinflammation. – 2020. – Vol. 17. – №. 1. -p. 1–11
186. 186. Jolly A. E. et al. Detecting axonal injury in individual patients after traumatic brain injury //Brain. – 2020
187. 187. Graham N. S. N. et al. Diffuse axonal injury predicts neurodegeneration after moderate-severe traumatic brain injury //Brain. – 2020. -Vol. 143. – №. 12. -p. 3685–3698
188. 188. Cardim D. et al. Effects of age and sex on optic nerve sheath diameter in healthy volunteers and patients with traumatic brain injury //Frontiers in Neurology. – 2020. -Vol. 11. -p. 764
189. 189. Cusimano M. D. et al. A population-based study of fall-related traumatic brain injury identified in older adults in hospital emergency departments //Neurosurgical focus. – 2020. -Vol. 49. – №. 4. -p. E20
190. 190. van Gils A. et al. Management of mild traumatic brain injury //Practical neurology. – 2020. -Vol. 20. – №. 3. -p. 213–221
191. 191. Bogner J. et al. Lifetime history of traumatic brain injury and behavioral health problems in a population-based sample //The Journal of head trauma rehabilitation. – 2020. -Vol. 35. – №. 1. -p. E43-E50
192. 192. Krishna G. et al. Approaches to monitor circuit disruption after traumatic brain injury: frontiers in preclinical research //International journal of molecular sciences. – 2020. -Vol. 21. – №. 2. -p. 588
193. 193. McIntire K. S. et al. Factors increasing the risk of suicide after traumatic brain injury: a state-of-the-science review of military and civilian studies //Brain injury. – 2021. -p. 1–13
194. 194. Serafini R. A., Pryce K. D., Zachariou V. The mesolimbic dopamine system in chronic pain and associated affective comorbidities //Biological psychiatry. – 2020. -Vol. 87. – №. 1. -p. 64–73
195. 195. Wager J. et al. Prevalence and associated psychosocial and health factors of chronic pain in adolescents: Differences by sex and age //European Journal of Pain. – 2020. -Vol. 24. – №. 4. -p. 761–772
196. 196. Cherif F. et al. Depression prevalence in neuropathic pain and its impact on the quality of life //Pain Research and Management. – 2020. -Vol. 2020.
197. 197. Harrisson S. A. et al. Prevalence, Characteristics, and Clinical Course of Neuropathic Pain in Primary Care Patients Consulting with Low Backrelated Leg Pain //The Clinical Journal of Pain. – 2020. -Vol. 36. – №. 11. -p. 813–824
198. 198. Koster-Brouwer M. E. et al. Occurrence and risk factors of chronic pain after critical illness //Critical care medicine. – 2020. -Vol. 48. – №. 5. -p. 680–687
199. 199. Freynhagen R., Rey R., Argoff C. When to consider «mixed pain»? The right questions can make a difference! //Current Medical Research and Opinion. – 2020. -Vol. 36. – №. 12. -p. 2037–2046
200. 200. Liampas A. et al. Prevalence and management challenges in central post-stroke neuropathic pain: A systematic review and meta-analysis //Advances in therapy. – 2020. -Vol. 37. -p. 3278–3291
201. 201. Gruener H. et al. Biomarkers for predicting central neuropathic pain occurrence and severity after spinal cord injury: results of a long-term longitudinal study //Pain. – 2020. -Vol. 161. – №. 3. -p. 545–556
202. 202. Yilmazer, C. et al. Clinical perspective on pain in multiple sclerosis//Multiple Sclerosis Journal. SAGE Publications-2020, p. 135245852095201. doi: 10.1177/1352458520952015.
203. 203. Viswanath O. et al. Central neuropathic mechanisms in pain signaling pathways: current evidence and recommendations //Advances in therapy. – 2020. -Vol. 37. – №. 5. -p. 1946–1959
204. 204. Moisset X. et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations //Revue Neurologie. – 2020. -Vol. 176. – №. 5. -p. 325–352
205. 205. Selvy M. et al. The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double blind, placebo-controlled, randomized clinical trials //Expert opinion on drug safety. – 2020. -Vol. 19. – №. 6. -p. 707–733
206. 206. Hall O. M. et al. Novel Agents in Neuropathic Pain, the Role of Capsaicin: Pharmacology, Efficacy, Side Effects, Different Preparations //Current Pain and Headache Reports. – 2020. -Vol. 24. – №. 9. -p. 1–12